Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study J Clin Oncol
Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease Rev Esp Patol
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison Adv Ther
First-line treatment of multiple myeloma in both transplant and non-transplant candidates EXPERT REV ANTICANC
Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia CYTOM PART B-CLIN CY
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials Blood Adv
Biomarkers found in the tumor interstitial fluid may help explain the differential behavior among keratinocyte carcinomas Mol Cell Proteomics
Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling Biomed Pharmacother
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era BONE MARROW TRANSPL